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ABSTRACT
Aims/Introduction: Cardiovascular autonomic neuropathy (CAN) is a predictor of cardiovascular disease and mortality. Cardiovascular reflex tests (CARTs) are the gold standard
for the diagnosis of CAN, but might not be feasible in large research cohorts or in clinical
care. We investigated whether measures of heart rate variability obtained from standard
electrocardiogram (ECG) recordings provide a reliable measure of CAN.
Materials and Methods: Standardized CARTs (R-R response to paced breathing, Valsalva, postural changes) and digitized 12-lead resting ECGs were obtained concomitantly
in Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and
Complications participants (n = 311). Standard deviation of normally conducted R-R intervals (SDNN) and the root mean square of successive differences between normal-tonormal R-R intervals (rMSSD) were measured from ECG. Sensitivity, specificity, probability
of correct classification and Kappa statistics evaluated the agreement between ECGderived CAN and CARTs-defined CAN.
Results: Participants with CARTs-defined CAN had significantly lower SDNN and rMSSD
compared with those without CAN (P < 0.001). The optimal cut-off points of ECG-derived
CAN were <17.13 and <24.94 ms for SDNN and rMSSD, respectively. SDNN plays a dominant role in defining CAN, with an area under the curve of 0.73, indicating fair test performance. The Kappa statistic for SDNN was 0.41 (95% confidence interval 0.30–0.51) for the
optimal cut-off point, showing fair agreement with CARTs-defined CAN. Combining SDNN
and rMSSD optimal cut-off points does not provide additional predictive power for CAN.
Conclusions: These analyses are the first to show the agreement between indices of
heart rate variability derived from ECGs and the gold standard CARTs, thus supporting
potential use as a measure of CAN in clinical research and clinical care.

INTRODUCTION
The Diabetes Control and Complications Trial/Epidemiology of
Diabetes Interventions and Complications (DCCT/EDIC) study
showed that intensive glycemic control lowered the risk of
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cardiovascular autonomic neuropathy (CAN) in type 1 diabetes
patients by 45% over the 6.5 years average follow-up period of
DCCT, and that this reduced risk persisted through an additional
13 years in the EDIC observational follow-up study1. Although
often overlooked in practice, CAN has serious consequences, as it
is an independent predictor of myocardial dysfunction2, cardiovascular disease (CVD)3,4 and mortality5,6 in diabetes.
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The gold standard for diagnosis of CAN involves several
standardized cardiovascular reﬂex tests (CARTs), including R-R
response to deep breathing, the Valsalva maneuver and postural
changes in blood pressure7. Alternative tests, such as indices of
heart rate variability (HRV) obtained from long-term Holtertype electrocardiogram (ECGs), have also been proposed to
evaluate CAN8. However, these tests are cumbersome to carry
out, and might not be easily implemented in clinical practice.
More recently, HRV-derived indices from standard 10-s 12lead ECG recordings have emerged as more feasible alternative
measures of CAN in population studies, and have been shown
to independently predict CVD morbidity and mortality in several large cohorts of people with diabetes5,6. However, rigorous
validation studies evaluating the sensitivity and speciﬁcity of
these ECG-based HRV indices compared with the gold standard CARTs assessment have not yet been reported.
Herein, we assessed whether optimal diagnostic thresholds
for indices of HRV derived from standard 10-s 12-lead ECG
recordings could provide a reliable measure of CAN in type 1
diabetes. The DCCT/EDIC study provides a unique opportunity
to leverage concomitantly acquired standardized cardiovascular
reﬂex tests and ECG recordings to address this question in a
large cohort of individuals with type 1 diabetes.

MATERIALS AND METHODS
Participants

The DCCT/EDIC study has been previously described in
detail9,10. Brieﬂy, 1,441 individuals with type 1 diabetes enrolled
in the DCCT (aged 13–39 years) were randomly assigned to
receive either intensive (n = 711) or conventional (n = 730)
diabetes therapy. At the end of DCCT (average follow-up period of 6.5 years), participants in the conventional therapy group
were taught intensive therapy, and all participants returned to
their own healthcare providers for ongoing diabetes care11. In
1994, 1,375 (96%) of the surviving DCCT cohort enrolled in
the EDIC observational study, and 1,202 (89%) of the surviving
cohort continued to actively participate in EDIC year 16 or 17
(2009–2010). In 2010, concurrent CARTs and ECG data were
available for 1,089 of these participants (Figure S1).
The George Washington University Committee on Human
Research approved the present study (approval number/ID:
IRB #040637; approval granted on 10 January 2017).
CARTs-deﬁned CAN evaluations

The DCCT/EDIC study utilized the following CARTs as part
of the protocol: deep breathing test (with pacing), Valsalva
maneuver and the lying-to-standing (postural) test, with assessments of the heart rate variation (R-R response) and blood
pressure response during administration. These tests are considered the gold standard tests for CAN, as endorsed by the Toronto Consensus on Diabetic Neuropathy and the American
Diabetes Association7,12. These assessments were obtained at
DCCT baseline, and DCCT years 2, 4, 6 and 8, and at EDIC
years 13/14 and 16/171,13,14. Participants were required to fast,
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and avoid caffeine and tobacco products, as well as prescription
medications (except for their usual insulin regimens), for at
least 8 h before CARTs testing. Testing was carried out using
the Hokanson ANS2000 devices (Hokanson Inc., Bellevue, WA,
USA) and results were analyzed centrally.
CAN, the primary outcome, was deﬁned as either an R-R
variation <15, or an R-R variation between 15–19.9 in combination with a Valsalva ratio ≤1.5, or a decrease of
>10 mmHg in diastolic blood pressure during 10 min of
standing, consistent also with our prior CAN analyses in this
large cohort1,14.
ECG

Twelve-lead resting ECGs were obtained at DCCT baseline,
biennially during the DCCT, at DCCT closeout and annually
during EDIC using a standardized procedure with the participant at rest in the supine position15. ECG tracings were processed centrally at the ECG Reading Center, initially at the
University of Minnesota ECG Reading Center (Minneapolis,
MN, USA; DCCT baseline to EDIC year 12) and thereafter at
the Epidemiological Cardiology Research (EPICARE) Center at
Wake Forest School of Medicine (Winston-Salem, NC, USA).
In EDIC year 16–17, the former analog paper-based ECG
recordings were replaced with digital recordings using GE
MAC 1200 electrocardiographs (GE, Milwaukee, WI, USA).
Digital ECGs were transmitted electronically through analog
phone lines to the ECG Reading Center. After visual inspection
for technical errors and quality, digital ECGs were automatically
processed using the 2001 version of the GE Marquette 12-SL
program (GE). Using the automatically measured R-R intervals,
two time-domain HRVs were calculated: (i) the standard deviation of normally conducted R-R intervals (SDNN); and (ii) the
root mean square of successive differences between normal-tonormal R-R intervals (rMSSD). The EPICARE ECG Reading
Center digitized the paper ECG tracings that could not be read
automatically using the Marquette 12-SL program (GE), and
developed customized software to derive HRV. Following the
recommended standards for measurements of HRV8, only the
ECGs from participants in sinus rhythm were used, and ECGs
with arrhythmias, conduction defects and >50% ectopic beats
were excluded. The automated measurement of HRV excluded
the beat before and the beat after ectopic beats from the HRV
measurements. Lower SDNN and rMSSD represented worse
autonomic function.
DCCT/EDIC evaluations

The DCCT/EDIC Central Biochemistry Laboratory (University
of Minnesota, Minneapolis, MN, USA) carried out all laboratory measurements with standardized methods and quality control assessments. Glycated hemoglobin (HbA1c) was measured
quarterly during DCCT and annually during EDIC using highperformance liquid chromatography. The time-weighted mean
HbA1c was calculated with weights proportional to the timeinterval between visits (1/4 during DCCT, and 1 during EDIC).
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Statistical analysis

Among the 1,089 DCCT/EDIC participants with concurrent
CAN and ECG measurements at EDIC year 16/17, a simple
random sample of 350 participants (Figure S1) was selected
for analysis. In this sample, the HRV indices could not be
calculated for a total of 39 participants (11%) due to the presence of arrhythmias (n = 8) or poor ECG recording quality
(n = 31). The prevalence of CAN was 39% at EDIC year 16/
17. The effective sample size of 311 provides approximately
80% power to detect a difference of approximately 0.15 in
Kappa value (e.g., 0.35 to 0.5), and a difference of 0.5 standard deviations in a quantitative variable (e.g., age and
HbA1c) between readable (n = 311) and un-readable (n = 39)
ECGs.
Two approaches for SDNN and rMSSD measures of ECGderived CAN were used. Based on the prevalence of 39% for
CAN at EDIC year 16/17, we ﬁrst deﬁned SDNN and rMSSD
measures using the 39th percentiles of SDNN and rMSSD,
respectively. The second approach classiﬁed each participant
into whichever class (i.e., CAN present or not) had the greatest
posterior probability, with optimal cut-off points determined
using the Bayes decision rule, as to maximize the probability of
correct classiﬁcation16–18. The probability of correct classiﬁcation was computed as the {(prevalence 9 sensitivity) + [(1 - prevalence) 9 speciﬁcity]}, where the prevalence
was 39%, estimated from the EDIC year 16/17 gold standard
CAN evaluation.
To assess whether SDNN and rMSSD can provide a reliable
measure of CAN, we evaluated the sensitivity, speciﬁcity, probability of a correct classiﬁcation and the Kappa statistic of each
measurement in predicting CAN using the gold standard
CART. Sensitivity is the probability of having a positive predicted CAN outcome (based on SDNN or rMSSD) in the presence of CAN assessed by CARTs. Speciﬁcity is the probability
of having a negative predicted CAN outcome (based on SDNN
or rMSSD) in the absence of CAN, as assessed by CARTs. The
Kappa statistic evaluated the agreement between CAN, as
assessed by CART, and by SDNN and rMSSD. A receiver operating characteristic curve for SDNN was constructed to represent the relationship between the true positive ratio (sensitivity)
and the false positive ratio (1-speciﬁcity). The area under the
receiver operating characteristic curve (AUC) was used to measure the performance of HRV from ECG (e.g., SDNN) in predicting CAN. An AUC value of 0.5 indicates random
predictions, whereas an AUC value of 1 indicates perfect prediction. AUC values between 0.70 and 0.79 indicate fair performance.
Separate logistic regression models, adjusted for sex and
attained age, assessed whether the associations between mean
HbA1c, attained type 1 diabetes duration, systolic blood pressure and any sustained albumin excretion rate (AER)
≥30 mg/day, with the CARTs-deﬁned CAN, were similar to the
associations between these risk factors and the ECG-derived
CAN. Two-sided P-values <0.05 were considered nominally
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signiﬁcant. All analyses used SAS software (version 9.4; SAS
Institute, Cary, NC, USA).

RESULTS
The characteristics of the evaluable EDIC cohort (n = 1,089)
that had simultaneous evaluations of CAN by CARTs and
ECG at EDIC year 16/17, and the randomly selected sample of
350 participants are presented in Table S1. The random sample
of 350 participants and 1089 EDIC evaluable cohort were similar in terms of age (51 – 7 vs 51 – 7 years), sex (43% vs 47%
female) and mean HbA1c (7.9 – 1.0 vs 8.0 – 1.0%). Additionally, the characteristics of the 311 participants with valid HRV
indices by ECG were similar to the 350 random sample participants and to the 1,089 evaluable EDIC cohort. However, the 39
participants without readable ECGs were slightly older
(53 – 7 years; P = 0.0434) and had higher mean HbA1c levels
(8.2 – 0.7%; P = 0.0276) compared with 311 participants with
readable ECG. Of the 311 participants included in these analyses, 120 (38.6%) had CAN based on the gold standard CARTs
assessment, compared with 16 (41%) of the 39 participants
excluded; there was no difference in beta-blocker use between
these groups (data not shown).
Figure 1 shows the density plots of SDNN and rMSSD, and
their scatter plots separately by CAN status (present/absent). At
EDIC year 16/17, the cut-off points based on ECG using the
39% prevalence of CAN were <17.67 and <22.86 ms for SDNN
and rMSSD, respectively, and the optimal cut-off points were
<17.13 and < 24.94 ms for SDNN and rMSSD, respectively.
Table 1 shows the association between CARTs and the two
HRV measurements, SDNN and rMSSD. Participants with
CAN had signiﬁcantly lower SDNN (18.5 – 11.0 vs
27.3 – 13.8 ms, p < 0.0001) and rMSSD (25.0 – 13.3 vs
32.3 – 15.8 ms, P < 0.0001) relative to participants without
CAN.
Table 2 presents the sensitivity, speciﬁcity and probability of
correct classiﬁcation of HRV indices in predicting CAN, as well
as the Kappa statistics for agreement between HRV indices and
CAN. Five thresholds are presented, two for the 39% cut-offs
and two for the optimal cut-offs for SDNN and rMSSD separately, and then using the optimal cut-offs for SDNN and
rMSSD combined.
Using the 39% prevalence cut-off thresholds, the SDNN and
rMSSD had 63.3 and 51.7% sensitivity, 77 and 69.6% speciﬁcity,
and 71.7 and 62.7% probability of correct classiﬁcation, respectively. Likewise, using the optimal individual cut-off thresholds,
the SDNN and rMSSD had 61.7 and 65.8% sensitivity, 78.5
and 63.4% speciﬁcity, and 72 and 64.3% probability of correct
classiﬁcation, respectively. Using the optimal combined cut-off
thresholds, the sensitivity, speciﬁcity and the probability of correct classiﬁcation were 61.7, 78.5 and 72%, respectively.
For the ECG-derived CAN measure based on SDNN, the
Kappa statistic was 0.40 (95% conﬁdence interval [CI] 0.30–
0.51) for the 39% prevalence cut-off threshold, and 0.41 (95%
CI 0.30–0.51) for the optimal cut-off threshold. Likewise, for
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Figure 1 | (a) Density and (b) scatter plots for standard deviation of normally conducted R-R intervals (SDNN) and root mean square of successive
differences between normal-to-normal R-R intervals (rMSSD) among cardiovascular autonomic neuropathy (CAN) present (CAN = 1) or absent
(CAN = 0).
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Table 1 | Distribution of electrocardiogram-derived heart rate variability overall and by cardiovascular autonomic neuropathy presence among a
random sample from the Epidemiology of Diabetes Interventions and Complications cohort
CAN Present

Total
Yes
No

SDNN

rMSSD

n

Mean – SD

P-value

n

Mean – SD

P-value

311
120
191

23.9 – 13.5
18.5 – 11.0
27.3 – 13.8

<0.0001

311
120
191

29.5 – 15.3
25.0 – 13.3
32.3 – 15.8

<0.0001

CAN, cardiovascular autonomic neuropathy; rMSSD, root mean square of the successive differences between all normal-to-normal R-R intervals (ms);
SD, standard deviation; SDNN, standard deviation of all normal-to-normal R-R intervals (ms).

the ECG-derived CAN measure based on rMSSD, the Kappa
statistic was 0.21 (95% CI 0.10–0.32) for the 39% prevalence
cut-off threshold, and 0.28 (95% CI 0.17–0.38) for the optimal
cut-off threshold.
To further assess whether the ECG-deﬁned CAN indices can
be used as a reliable measure of CAN (present or absent), we
compared the individual associations between SDNN and risk
factors (time-weighted mean HbA1c, attained type 1 diabetes
duration, systolic blood pressure and any sustained AER
≥30 mg/dL) to the individual associations between CAN and
these risk factors. Adjusted for age and sex, the magnitude and
strength of the association between the SDNN-derived CAN
(SDNN-CAN) and associated risk factors were similar to using
CARTs-deﬁned CAN (Table 3).
Figure 2 shows the receiver operating characteristic curve for
the performance of SDNN in predicting CAN. The AUC using
the SDNN optimal cut-off was 0.73, indicating a fair test performance for detecting CAN.
We then investigated the associations between time-weighted
mean HbA1c, attained duration of type 1 diabetes, systolic
blood pressure and any sustained AER ≥30 mg/dL with
SDNN-CAN separately among those with CAN present, and
then among those with CAN absent (Table 4). None of the
associations were signiﬁcant among those with CAN absent,
whereas higher time-weighted mean HbA1c values and the
presence of any sustained AER ≥30 mg/dL were associated with
higher odds of a positive SDNN-CAN outcome among participants with CAN present (i.e., with higher sensitivity). These
ﬁndings suggest that the SDNN is a better measure of CAN
among individuals with higher glycemic levels and presence of
any sustained AER≥30 mg/dL. Further analyses conﬁrmed that
the Kappa value was signiﬁcantly higher among participants
with time-weighted mean HbA1c values >8% compared with
≤8% (Kappa = 0.50 vs 0.2332, P = 0.0162), but not signiﬁcant
for any sustained AER ≥30 mg/dL versus not (Kappa = 0.46 vs
0.33, P = 0.3095) when glycemia was not included (data not
shown).

DISCUSSION
In the present study, we report the ﬁrst rigorous assessment of
the sensitivity, speciﬁcity and probability of correct classiﬁcation
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of CAN using indices of HRV derived from short ECG recordings in predicting CAN compared with the more laborious
method using the gold standard cardiovascular reﬂex testing.
The DCCT/EDIC participants with CAN had signiﬁcantly
lower SDNN and rMSSD compared with those without CAN,
and the probabilities of correct classiﬁcation using either the
39% prevalence or the optimal cut-off thresholds were higher
for SDNN than rMSSD. Of the two HRV measures, SDNN
played the dominant role in deﬁning CAN, with an AUC of
0.73, showing fair test performance. Combining optimal cut-off
points for both SDNN and rMSSD did not provide additional
predictive power for CAN.
Using data from the DCCT/EDIC cohort, we derived optimal cut-offs for SDNN and rMSSD using the standardized deﬁnition of CAN based on CARTs. It is notable these cut-offs
differ from the reported sex- and race-speciﬁc reference ranges
for SDNN and rMSSD obtained from the same standard 12lead ECG recordings in the Multi-Ethnic Study of Atherosclerosis (MESA). In approximately 1,700 MESA participants aged
≥45 years, SDDN cut-offs of 6.1 and 8.2 ms, and rMSSD cutoffs of 6 and 8 were deﬁned as abnormal and borderline,
respectively19, which are substantially lower than the cut-offs
identiﬁed herein. However, it is important to note that the
MESA SDNN and rMDDS cut-offs were deﬁned in a sample
of participants free of any CVD or CVD risk factors, including
diabetes, and then validated in the entire MESA cohort. The
abnormal and borderline values were computed based on the
sex- and race-speciﬁc second and ﬁfth percentiles, respectively,
in lieu of the gold standard CARTs for CAN which was not
available19. Among 311 DCCT/EDIC participants, the second
and ﬁfth percentiles were 7.8 and 9.1 ms for SDNN, and 11.3
and 13.4 ms for rMDDS, respectively. These were slightly
higher than the cut-off points deﬁned as abnormal and borderline in the MESA study. However, in contrast to the participants in the DCCT/EDIC study who all had type 1 diabetes
and were predominantly (93%) white, the MESA participants
were 38% white, 27% black, 23% Hispanic and just 14% with
type 2 diabetes. In a cohort of participants in the MESA study
who were generally healthy and free of CVD risk factors,
including diabetes, the normative cut-offs are expected to be
much lower than those derived in the DCCT/EDIC cohort of
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CAN, cardiovascular autonomic neuropathy; CI, confidence interval; ECG, electrocardiogram; rMSSD, root mean square of the successive differences between all normal-to-normal R-R
intervals (ms); SDNN, standard deviation of all normal-to-normal R-R intervals (ms).

0.28 (0.17, 0.38)
0.21 (0.10, 0.32)
0.41 (0.30, 0.51)
0.40 (0.30, 0.51)
Kappa statistic

Kappa (95% CI)
Kappa (95% CI)
Kappa (95% CI)

Kappa (95% CI)

61.7
78.5
72.0
63.3
77.0
71.7

51.7
69.6
62.7

65.8
63.4
64.3

61.7
78.5
72.0
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Sensitivity (%)
Specificity (%)
Probability of correct classification (%)

CAN prevalence (39% cut-off)
CAN prevalence (39% cut-off )

Optimal cut-off

rMSSD
SDNN

ECG-derived Indices
CAN

Table 2 | Sensitivity, specificity, probability of correct classification, and kappa statistic for electrocardiogram-derived indices

Optimal cut-off

Both

Optimal cut-off
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participants with type 1 diabetes of >20 years. The cut-offs
were determined in this DCCT/EDIC study were based on gold
standard CARTs-deﬁned CAN, which was not available in the
MESA study. As the CAN prevalence in the present cohort
was 39% (much higher than the 2 and 5% assumed in the
MESA study), it is not unexpected that the cut-off values identiﬁed in this type 1 diabetes cohort are much higher than those
deﬁned in the MESA study.
An important beneﬁt of having reliable and easily obtained
measures to assess CAN in large cohort studies or clinical trials,
is their use for participant phenotyping for chronic complications including CAN, and for risk stratiﬁcation. For instance,
the Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trial showed that SDNN values in the lowest quartile (<7.185 ms) combined with prolonged QT intervals were
independently associated with an increased risk for CVD and
all-cause mortality in participants with type 2 diabetes5,
whereas in the MESA cohort, abnormal HRV values were
strongly associated with CVD events and all-cause mortality19.
These same indices were recently used to assess the prevalence
of CAN in a large contemporary cohort of patients with type 2
diabetes of short duration participating in the Glycemia Reductions Approaches in Diabetes (GRADE) study, and the prevalence rate for CAN was comparable with data from other
cohorts with early type 2 diabetes, such as the ADDITION
study, where CAN was assessed with traditional CARTs20,21.
The strengths of the present analyses include the detailed
and comprehensive phenotypic assessments of the DCCT/EDIC
cohort over a period of >30 years, which included concomitant
cardiovascular reﬂex tests for CAN and digitized ECGs, which
were not available in other large cohort studies with diabetes.
The sensitivity and speciﬁcity of the SDNN cut-offs validated
herein might not be ideal, which could limit their applicability.
However, they do show fair predictive performance comparable
with other instruments that have been used successfully to phenotype diabetic peripheral neuropathy in large and diverse
cohorts of patients with type 1 and type 2 diabetes21–25. As
with any other study, the present ﬁndings apply to populations
similar to the cohort used herein (i.e., middle aged, mostly
white individuals with type 1 diabetes), and generalizing these
results to other populations (e.g., adolescents or individuals with
type 2 diabetes) necessitates further study.
These DCCT/EDIC analyses are the ﬁrst to show the level of
agreement between indices of HRV derived from standard
ECGs and the gold standard CARTs. The present ﬁndings provide some support for use of HRV derived from standard
ECGS as a measure of CAN in clinical research, particularly in
studies involving large cohorts or those where assessment using
CARTs is not feasible or available. In addition, the relatively
straightforward approach in obtaining the ECGs derived HRV
can be more easily translated into clinical care practices, and
especially useful in evaluating those patients with type 1 diabetes with suboptimal glycemic control and higher risk factor
proﬁles for other complications.
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Table 3 | Associations of selected risk factors with cardiovascular autonomic neuropathy and standard deviation of all normal-to-normal R-R
intervals† in separate logistic regression models‡
Risk factor

CAN (yes vs no)

Weighted mean HbA1c (%)
Attained duration (years)
Systolic blood pressure (mmHg)
Any sustained AER ≥30 (mg/dL, yes vs no)

SDNN (yes vs no)

Odds ratio (95% CI)

Wald v

P-value

Odds ratio (95% CI)

Wald v2

P-value

1.80
1.04
1.03
3.85

21.8
2.0
9.6
21.3

<0.0001
0.1606
0.0020
<0.0001

1.91
1.02
1.02
3.51

25.2
0.6
5.4
19.1

<0.0001
0.4332
0.0196
<0.0001

(1.41–2.30)
(0.99–1.09)
(1.01–1.04)
(2.17–6.83)

2

(1.48–2.46)
(0.97–1.07)
(1.00–1.04)
(2.00–6.15)

AER, albumin excretion rate; CAN, cardiovascular autonomic neuropathy; CI, confidence interval; HbA1c, glycated hemoglobin. †Using the optimal
cut-off for standard deviation of all normal-to-normal R-R intervals(SDNN). ‡Adjusted for age and sex.
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Lakes, NJ, USA), Eli Lilly (Indianapolis, IN, USA), Extend
Nutrition (St. Louis, MO, USA), Insulet Corporation (Bedford,
MA, USA), Lifescan (Milpitas, CA, USA), Medtronic Diabetes
(Minneapolis, MN, USA), Nipro Home Diagnostics (Ft. Lauderdale, FL, USA), Nova Diabetes Care (Billerica, MA, USA),
Omron (Shelton, CT, USA), Perrigo Diabetes Care (Allegan,
MI, USA), Roche Diabetes Care (Indianapolis, IN, USA) and
Sanoﬁ-Aventis (Bridgewater, NJ, USA).
The DCCT/EDIC has been supported by cooperative agreement grants (1982-1993, 2012-2017, 2017-2022) and contracts
(1982-2012) with the Division of Diabetes Endocrinology and
Metabolic Diseases of the National Institute of Diabetes and
Digestive and Kidney Disease (current grant numbers U01
DK094176 and U01 DK094157), and through support by the
National Eye Institute, the National Institute of Neurologic
Disorders and Stroke, the General Clinical Research Centers

ROC Curve for Model
Area Under the Curve = 0.7310
1.00

Sensitivity

0.75

0.50

0.25

0.00
0.00

0.25

0.50

0.75

1.00

1 - Specificity

Figure 2 | Receiver operating characteristic (ROC) curve for standard
deviation of normally conducted R-R intervals (SDNN).

Table 4 | Associations between risk factors and standard deviation of all normal-to-normal R-R intervals† by cardiovascular autonomic neuropathy
status (absent/present) in separate logistic regression models‡
SDNN (CAN absent)

Weighted mean HbA1c (%)
Attained duration (year)
Systolic blood pressure (mmHg)
Any sustained AER ≥ 0 (yes vs no)

SDNN (CAN present)

OR (95% CI)

Wald v

P-value

OR (95% CI)

Wald v2

P-value

1.27
1.00
1.00
1.86

1.3
0.0
0.1
1.9

0.2549
0.9747
0.7391
0.1730

2.01
1.01
1.02
3.16

13.0
0.1
1.3
6.4

0.0003
0.7270
0.2510
0.0113

(0.84–1.90)
(0.93–1.07)
(0.98–1.03)
(0.76– 4.52)

2

(1.37–2.93)
(0.94–1.10)
(0.99–1.04)
(1.30–7.69)

AER, albumin excretion rate; CAN, cardiovascular autonomic neuropathy; CI, confidence interval; HbA1c, glycated hemoglobin. †Using the optimal
cut-off for standard deviation of all normal-to-normal R-R intervals(SDNN). ‡Adjusted for age and sex.
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Program (1993-2007), and Clinical Translational Science Center
Program (2006 to present), Bethesda, Maryland, USA.
Data collected for the DCCT/EDIC study through 30 June
2017 are available to the public through the NIDDK Repository
(https://repository.niddk.nih.gov/studies/edic/). Data collected in
the current cycle (July 2017 to June 2022) will be available
within 2 years after the end of the funding cycle.
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SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.
Figure S1 | Cardiovascular autonomic neuropathy (CAN)† electrocardiogram (ECG)-heart rate variability (HRV)‡ sample.
Table S1 | Distributions of age and time-weighted mean glycated hemoglobin overall and by sex.
Appendix S1 | Complete listing of participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.
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